Prescription Reform Resources
Find resources tagged to:
Access to Medicines | Conflicts of Interest | Marketing | Quality
A majority of patients under age 65 face high and increasing out-of-pocket medication costs that interfere with their
treatment. We investigated primary care physicians’ interest in a model web-based comparative drug pricing resource. This report reveals that these drugs were subject to an industry practice called "pay for delay," in which brand name pharmaceutical companies pay off generic drug manufacturers to keep lower cost equivalents off the market, forcing consumers to pay highe The Physician Payments Sunshine provisions in the Affordable Care Act require drug and medical device manufacturers to publicly report gifts and payments made to physicians and teaching hospitals. This toolkit provides a guide to the process of COI policy development and implementation. The toolkit discusses the importance of making professionalism your central tenet, developing a good process, as well as other key concepts. In this toolkit, the ways in which gifts create bias and undermine professionalism are discussed, along with widely adopted recommendations for prohibition by medical leaders. Promotional speaking (speakers bureaus) is the practice of pharmaceutical companies recruiting and training physicians to give talks promoting company products. This toolkit recommends a ban to maintain the integrity of patient care and clinical research, In this toolkit the prevalence and impact of these industry practices are discussed, along with arguments that have been made for and against meeting with sales representatives. Policy solutions and model policies are presented, ranging from exclusion to This toolkit addresses the practice of fraudulently hiding the true identity of authors in medical research and publishing. Policy and enforcement recommendations, a checklist for preventing this practice, and two model policies are included. This toolkit addresses the issue of pharmaceutical and device industry support for continuing medical education. It outlines concerns about the effects of such support on the information that clinicians receive through CME programs and subsequent bias in Community Catalyst is a partner in a three-year initiative, the Partnership to Advance ConflictFree Medical Education (PACME), launched in 2011 to address the need for improvements in conflict-of-interest standards at the approximately 150 medical schools This toolkit provides the rationale for teaching about conflict of interest in medical schools and residency programs and a succinct overview of the competencies learners should achieve, along with the theory supporting various educational approaches. It These toolkits are provided to assist leaders, faculty, staff and medical students in successfully adopting and improving policies to address conflicts of interest and interactions with the pharmaceutical and device industries. Policies such as these and Under the Physician Payments Sunshine Provision, manufacturers of drugs, devices, biologics or medical supplies, or their subsidiaries that sell these products in the United States, must report to Health and Human Services certain payments made to physici Eight national organizations in addition to Community Catalyst sent this letter to all members of the House of Representatives in support of the Drug Safety Enhancement Act of 2011, HR 1483. Comments of Community Catalyst and six additional organizations on the FDA's draft strategic priority of strengthening the safety and integrity of the global supply chain. In recent years there have been a number of incidents pointing to the safety concerns of over-the-counter drugs. In 2009, a record 1,742 drugs -- including 50 dietary supplements -- were recalled, four times the number recalled in 2008.1 Many of these invAccess to Medicines
Evaluation of a Model Comparative Drug Price Resource in Fostering Prescriber - Patient Engagement, Lowering Consumer Costs and Improving Adherence
Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers
Generic Pharmaceutical Association: Savings Achieved Through the Use of Generic Pharmaceuticals, 2000-2009
[ Resource ]
Consumer Reports Best Buy Drugs
[ Resource ]
National Legislative Association on Prescription Drug Prices
[ Resource ]
Advancing Efficient Management and Purchasing of Prescription Drugs
[ Resource ]
Conflicts of Interest
The Physician Payments Sunshine Act Fact Sheet
Toolkit on Conflict of Interest Policy Implementation
Toolkit on Gifts, Meals and Entertainment
Toolkit on Speakers Bureaus
Toolkit on Relations with Sales Representatives
Toolkit on Ghostwriting and Name-Lending
Toolkit on Continuing Medical Education
Addressing Industry Conflicts-of-Interest at Academic Medical Institutions
Conflict-of-Interest Curriculum Toolkit
Conflict of Interest Policy Guide for Medical Schools and Academic Medical Centers
Marketing
Partnership to Advance Conflict-Free Medical Education
[ Resource ]
Letter to Secretary Sebelius Regarding Disclosure of Industry Payment to Physicians and Teaching Hospitals
Community Catalyst Statement on Supreme Court Decision Striking Down Vermont Law Protecting Prescription Records
[ Resource ]
NLARx Press Release: Supreme Court Overturns Vermont Prescription Records Privacy Law in Sorrell v. IMS Health
[ Resource ]
Amicus Brief, filed with the U.S. Supreme Court, in Support of Vermont Law Banning Data Mining
[ Resource ]
National Physicians Alliance
[ Resource ]
National Legislative Association on Prescription Drug Prices
[ Resource ]
Project on Information Justice and Intellectual Property
[ Resource ]
AMSA PharmFree Scorecard
[ Resource ]
Prescription Policy Choices
[ Resource ]
Colorado Prescription Coalition Seeks Pharma Marketing Reforms
[ Resource ]
Consumer Survey
[ Resource ]
National Coalition for Appropriate Prescribing
[ Resource ]
Sample Prescription Medications Fact Sheet
[ Resource ]
Why Small Gifts Matter Fact Sheet
[ Resource ]
Addressing Cost and Quality: The Physician Payments Sunshine Act
[ Resource ]
Prescription Record Privacy Act Model Bill
[ Resource ]
The Case for Disclosure
[ Resource ]
Pharmaceutical Industry Marketing Fact Sheet
[ Resource ]
Non-physician Prescribers and Pharmaceutical Industry Interactions
[ Resource ]
Prescriber Profiling Testimony in Maryland, Dec. 2008
[ Resource ]
Prescription Data Mining Fact Sheet
[ Resource ]
Regulating Industry Payments to Physicians: Identifying & Minimizing Conflicts Of Interest: Fact Sheet
[ Resource ]
PhRMA Marketing Code on Interactions with Healthcare Professionals: Old vs. New
[ Resource ]
Data Mining Amicus Curiae: IMS Health v. Sorrell
[ Resource ]
Data Mining and Medicaid Fact Sheet
[ Resource ]
Prescription Drug and Medical Device Marketing Restrictions and Disclosure Act Model Legislation
[ Resource ]
The Constitutional Battle over State Regulation of Data Mining
[ Resource ]
Data Mining Amicus Curiae: IMS Health v. Ayotte
[ Resource ]
Quality
Pew Health Group Report: "After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs"
[ Resource ]
Letter in Support of Drug Safety Enhancement Act
Summary of Drug Safety Enhancement Act of 2011, HR 1483
[ Resource ]
US Pharmacopeia: "USP Verified" Consumer Guide for Vitamins and Supplements
[ Resource ]
New York State's Medicaid Prescriber Education Program
[ Resource ]
Maine's Academic Detailing Program
[ Resource ]
Consumer Reports Best Buy Drugs
[ Resource ]
Consumers Union
[ Resource ]
National Physicians Alliance
[ Resource ]
Prescription Policy Choices
[ Resource ]
Independent Drug Information Services
[ Resource ]
National Resource Center for Academic Detailing
[ Resource ]
Council on Foreign Relations: Symposium on Food and Drugs: Can Safety Be Ensured in a Time of Increased Globalization?
[ Resource ]
Comments on FDA Supply Chain Strategic Priority
Safety of Over-the-Counter Drugs Fact Sheet
Safety of the Prescription Drug Supply Fact Sheet
[ Resource ]
Drug Safety and Accountability Act of 2010 Fact Sheet
[ Resource ]
Exposing the Gaps Fact Sheet
[ Resource ]
Alliace for a Safe Drug Supply: Statement of Principles
[ Resource ]
Pew Prescription Project: Securing a Safe Drug Supply
[ Resource ]
Drug Safety and Accountability Act of 2010
[ Resource ]
News Release on Drug Safety and Accountabilty Act of 2010 from Senator Bennet (D-CO)
[ Resource ]
Wisconsin Coalition Looks at Prescriber Education and Pharmaceutical Reforms
[ Resource ]
Minnesota Prescription Coalition Seeks Prescribing, Marketing Reforms
[ Resource ]
AARP: Rx Watchdog Report
[ Resource ]
National Coalition for Appropriate Prescribing (NCAP) Members
[ Resource ]
Evidence-Based Prescribing
[ Resource ]
Academic Detailing Fact Sheet
[ Resource ]
The Independent Drug Education and Outreach Act Fact Sheet
[ Resource ]
GAO report: Better data management, more inspections needed to strengthen FDA's foreign drug inspection program
[ Resource ]
Comments to FDA on Limitations and Risks of Direct-to-Consumer Advertising
[ Resource ]
Prescriber Education Model Legislation
[ Resource ]
Comments to FDA on Good Journal Reprint Practices
[ Resource ]
Cost-Effectiveness of Prescriber Education (Academic Detailing) Programs
[ Resource ]
Risk with No Benefit: The Marketing of Over-the-Counter Cough and Cold Medications for Children
[ Resource ]